Natasha Jain
Hematology & Oncology · Washington, DCNPI 1578981445
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $456, more than ten times the $22 reported in 2022. That places this record below the midpoint for hematology & oncology clinicians in DC, where the typical reported total is $4,025.
Across 34 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$143
- Novartis$86
- AbbVie$83
- Stemline Therapeutics Inc.$52
- Astellas Pharma US Inc$48
- Novo Nordisk$47
- plus $270 from 12 others
Across 151 payments — averaging $1053.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tolmar, Inc.$159K
What the payments were for
- Food & beverage$730100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 6 | $143 |
| Novartis | 4 | $86 |
| AbbVie | 3 | $83 |
| Stemline Therapeutics Inc. | 3 | $52 |
| Astellas Pharma US Inc | 2 | $48 |
| Novo Nordisk | 2 | $47 |
| Merck | 2 | $35 |
| Bayer | 2 | $31 |
| GSK | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Gilead | 1 | $24 |
| Iovance Biotherapeutics, Inc. | 1 | $23 |
| Amgen | 1 | $22 |
| Foundation Medicine, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Pfizer | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$730 in reported general payments places this provider in the 35th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 16 | $259,706 |
| CalquenceAcalabrutinib Maleate | 17 | $233,920 |
| XareltoRivaroxaban | 42 | $33,596 |
| Abiraterone Acetate | 12 | $32,197 |
| EliquisApixaban | 12 | $10,379 |
| Anastrozole | 155 | $2,111 |
| Tamoxifen Citrate | 20 | $831 |
| Hydroxyurea | 25 | $612 |
| Prochlorperazine Maleate | 25 | $366 |
| Ondansetron Hcl | 31 | $350 |
| Letrozole | 22 | $280 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $261 |
| Gabapentin | 14 | $183 |
| Prednisone | 11 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $16 | $233,92017 claims |
| PfizerEliquis | $16 | $10,37912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 69 hematology & oncology providers in District of Columbia.
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Craig KesslerWashington$449K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.